SEC Form 4 · accession 0000886163-18-000133
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew W Foehr
Officer — President and COO
Period of report
Sep 4, 2018
Accepted (ET)
Sep 5, 2018 · 8:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2018 | M | 1,044 | $9.97 | A | 103,300 | D | |
| Common StockF1 | Sep 4, 2018 | M | 12,000 | $14.47 | A | 115,300 | D | |
| Common StockF1,F2 | Sep 4, 2018 | S | 12,000 | $255.0068 | D | 103,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $9.97 | Sep 4, 2018 | M | 1,044 | D | — | Apr 18, 2021 | Common Stock | 1,044 | 39,982 | D |
| Employee Stock Option (right to buy)F1,F4 | $14.47 | Sep 4, 2018 | M | 12,000 | D | — | Feb 9, 2022 | Common Stock | 12,000 | 33,675 | D |
Explanation of responses
- F1The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.11 to $260.43, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
- F4Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.